Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TAR syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44297   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: TAR syndrome. Displaying page 1 of 1.
    EudraCT Number: 2007-006302-13 Sponsor Protocol Number: CT-BI Vacc-4x 2007/1 Start Date*: 2008-06-04
    Sponsor Name:Bionor Immuno AS
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART
    Medical condition: HIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005950-33 Sponsor Protocol Number: DOMPCCHSSWE1 Start Date*: 2006-06-07
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom.
    Medical condition: Congenital central hypoventilation syndrome, CCHS or Ondine's curse.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004506-64 Sponsor Protocol Number: 17000139BLC3002 Start Date*: 2023-01-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG...
    Medical condition: BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021356-26 Sponsor Protocol Number: 111679 Start Date*: 2011-01-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramus...
    Medical condition: ART-naïve HIV-infected adults (ART: anti-retroviral therapy)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001348-39 Sponsor Protocol Number: SEM-TAR-01-2014 Start Date*: 2014-12-03
    Sponsor Name:Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI)
    Full Title: A Phase II, randomized clinical trial to assess the impact of antiretroviral therapy over viral load in seminal fluid in antiretroviral-naive HIV-positive patients
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005506-23 Sponsor Protocol Number: NV18209 Start Date*: 2006-04-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 1...
    Medical condition: Pacientes con virus de la Hepatitis C crónica (HCC) del genotipo 1 coinfectados por virus de la inmunodeficiencia humana de tipo 1 (VIH-1).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006417-32 Sponsor Protocol Number: P04889 Start Date*: 2008-02-06
    Sponsor Name:Schering-Plough Research Institute
    Full Title: Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4)
    Medical condition: HIV infection (R5 tropism only) with previous therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10200172 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003133-16 Sponsor Protocol Number: P04875 Start Date*: 2008-02-15
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects
    Medical condition: HIV INFECTION IN NAIVE PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA